CORONA Remedies Limited Acquires Wokadine® Brand from Dr. Reddy's Laboratories in Strategic Deal

1 min read Updated on 31 Mar 2026, 05:28 AM

Reviewed by

Radhika SScanX News Team

AI Summary

CORONA Remedies Limited announced the strategic acquisition of Wokadine® from Dr. Reddy's Laboratories, effective March 30, 2026. This fifth acquisition enables entry into the INR 648 Cr Povidone Iodine market, where Wokadine® holds the #2 position. The brand comprises 14 SKUs and will be integrated into CORONA's existing portfolio to enhance market penetration across multiple medical specialties.

*this image is generated using AI for illustrative purposes only.

CORONA Remedies Limited has announced a strategic acquisition of the Wokadine® brand from Dr. Reddy's Laboratories Ltd., effective March 30, 2026. This transaction represents the company's fifth acquisition and marks its entry into the significant Povidone Iodine market segment.

Strategic Market Entry

The acquisition enables CORONA Remedies to enter the INR 648 Cr Povidone Iodine market, with Wokadine® holding the #2 position in this segment according to Pharmatrac MAT Feb'26 data. The brand brings a legacy of 46 years of trust and protection, positioning it as a valuable addition to CORONA's existing therapeutic portfolio.

Parameter:	Details
Acquisition Date:	March 30, 2026
Market Position:	#2 in Povidone Iodine India market
Market Size:	INR 648 Cr
Product Range:	14 SKUs with different applications
Funding Source:	Internal accruals and cash

Product Portfolio and Market Reach

Wokadine® comprises 14 SKUs with various applications, designed to help clinicians treat patients across different medical specialties. The acquisition increases CORONA Remedies' equity among surgeons, ENT specialists, general physicians, and gynaecologists. The brand's diverse product range aligns with CORONA's strategy of expanding its presence in targeted specialty areas.

CORONA Remedies plans to leverage its extensive sales and marketing team along with its pan-India distribution network to ensure the newly acquired portfolio reaches patients across metro, semi-metro, urban, semi-urban, and rural areas.

Management Commentary

Mr. Tejas Kothari, Vice President – Corporate Strategy & Business Development, commented on the strategic rationale: "At CORONA Remedies, we continuously assess both organic and inorganic growth opportunities, focusing on strengthening our brands by leveraging CORONA's extensive reach, strong trust among doctors and the medical fraternity, a pan-India distribution network, and a dedicated sales and marketing team."

He added: "We believe this acquisition will enhance and strengthen our existing product portfolio. By building on our strong relationships with healthcare professionals, we aim to deepen market penetration and are confident in accelerating the growth of this brand."

Company Background

CORONA Remedies Limited, founded in 2004, operates as an India-focused branded pharmaceutical formulation company. The company develops, manufactures, and markets products across women's healthcare, cardio-diabetes, pain management, urology, and other therapeutic areas. CORONA maintains WHO-GMP/EU GMP-certified manufacturing facilities and operates 2 DSIR-approved R&D centres with over 100 scientists working on new formulation development. The company employs more than 5,000 people across its operations.

Historical Stock Returns for Corona Remedies